A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Scleroderma, Systemic

Interventions

DRUG: Nintedanib
DRUG: Placebo

Sponsor

Boehringer Ingelheim